Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.70 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.60 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.60 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.60 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.54 |
| ▸ | MAOB | P27338 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | PPARD | Q03181 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30885868 | 1.00 | LMNA (0.70) | LMNAMTNR1AMTNR1BFFAR1FFAR4 | |
| SCHEMBL6320778 | 0.92 | FFAR1 (0.71) | LMNAMTNR1AMTNR1BFFAR1FFAR4 | |
| SCHEMBL31279580 | 0.92 | FFAR1 (0.71) | LMNAMTNR1AMTNR1BFFAR1FFAR4 | |
| SCHEMBL17261730 | 0.90 | LMNA (0.66) | LMNAMTNR1AMTNR1BFFAR1FFAR4 | |
| SCHEMBL8355748 | 0.89 | LMNA (0.64) | LMNAMTNR1AMTNR1BFFAR1FFAR4 | |
| SCHEMBL2741520 | 0.88 | LMNA (0.54) | LMNAMTNR1AMTNR1BFFAR1FFAR4 | |
| SCHEMBL24136195 | 0.86 | L3MBTL1 (0.61) | LMNAFFAR1FFAR4ALDH1A1L3MBTL1 | |
| SCHEMBL9559951 | 0.86 | CYP1A2 (0.62) | LMNAFFAR1FFAR4ALDH1A1L3MBTL1 | |
| Anisole SCHEMBL28094109 | 0.86 | MAPT (0.65) | LMNAFFAR1FFAR4ALDH1A1L3MBTL1 | |
| SCHEMBL22578056 | 0.85 | MCL1 (0.61) | LMNAFFAR1FFAR4ALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4598928-A1 | FOLLICLE-STIMULATING HORMONE RECEPTOR (FSHR) TARGETED THERAPEUTICS AND USES THEREOF | Radionetics Oncology, Inc. (US) | 2025-08-13 | — | — | EP | disclosed |
| WO-2024077006-A1 | FOLLICLE-STIMULATING HORMONE RECEPTOR (FSHR) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. (US) | 2024-04-11 | — | — | WO | disclosed |
| US-20200299306-A1 | COMPOUNDS WITH A BENZO[A]CARBAZOLE STRUCTURE AND USE THEREOF | UNIVERSITA' DI PISA (IT) | 2020-09-24 | — | — | US | disclosed |
| US-20100298306-A1 | (1,4-Diaza-bicyclo[3.2.2]non-6-en-4-yl)-heterocyclyl-methanone Ligands for Nicotinic Acetylcholine Receptors, Useful for the Treatment of Disease | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-11-25 | — | — | US | disclosed |
| US-20100298306-A1 | (1,4-Diaza-bicyclo[3.2.2]non-6-en-4-yl)-heterocyclyl-methanone Ligands for Nicotinic Acetylcholine Receptors, Useful for the Treatment of Disease | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-11-25 | — | — | US | disclosed |
| WO-2009055437-A9 | (1,4-DIAZA-BICYCLO[3.2.2]NON-6-EN-4-YL)-HETEROCYCLYL-METHANONE LIGANDS FOR NICOTINIC ACETYLCHOLINE RECEPTORS, USEFUL FOR THE TREATMENT OF DISEASE | MEMORY PHARM CORP (US) | 2009-07-23 | — | — | WO | disclosed |
| US-20090131384-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF DISORDERS ASSOCIATED WITH ER STRESS | SYNDEXA PHARMACEUTICALS CORPORATION (US) | 2009-05-21 | — | — | US | disclosed |
| US-20090131384-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF DISORDERS ASSOCIATED WITH ER STRESS | SYNDEXA PHARMACEUTICALS CORPORATION (US) | 2009-05-21 | — | — | US | disclosed |
| WO-2009055437-A2 | (1,4-DIAZA-BICYCLO[3.2.2]NON-6-EN-4-YL)-HETEROCYCLYL-METHANONE LIGANDS FOR NICOTINIC ACETYLCHOLINE RECEPTORS, USEFUL FOR THE TREATMENT OF DISEASE | MEMORY PHARMACEUTICALS CORPORATION (US) | 2009-04-30 | — | — | WO | disclosed |
| US-7354927-B2 | 6H-[1]benzopyrano[4,3-b]quinolines and their use as estrogenic agents | WYETH (US) | 2008-04-08 | — | — | US | disclosed |
| US-7354927-B2 | 6H-[1]benzopyrano[4,3-b]quinolines and their use as estrogenic agents | WYETH (US) | 2008-04-08 | — | — | US | disclosed |
| US-7354927-B2 | 6H-[1]benzopyrano[4,3-b]quinolines and their use as estrogenic agents | WYETH (US) | 2008-04-08 | — | — | US | disclosed |
| WO-2007111994-A2 | COMPOUNDS AND METHODS FOR TREATMENT OF DISORDERS ASSOCIATED WITH ER STRESS | SYNDEXA PHARMACEUTICALS CORPORATION (US) | 2007-10-04 | — | — | WO | disclosed |
| EP-1789420-A2 | 6H-[1]BENZOPYRANO[4,3-b]QUINOLINES AND THEIR USE AS ESTROGENIC AGENTS | Wyeth, A Corporation of the State of Delaware (US) | 2007-05-30 | — | — | EP | disclosed |
| WO-2006029146-A2 | 6H-[1]BENZOPYRANO[4,3-b]QUINOLINES AND THEIR USE AS ESTROGENIC AGENTS | WYETH (US) | 2006-03-16 | — | — | WO | disclosed |
| US-20060052410-A1 | 6H-[1]benzopyrano[4,3-b]quinolines and their use as estrogenic agents | WYETH (US) | 2006-03-09 | — | — | US | disclosed |
| EP-1091958-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2001-04-18 | — | — | EP | disclosed |
| WO-2000001692-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2000-01-13 | — | — | WO | disclosed |
| EP-0641792-A1 | 1,2-Dithiole derivatives and therapeutic agents containing them | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1995-03-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298306-A1 | (1,4-Diaza-bicyclo[3.2.2]non-6-en-4-yl)-heterocyclyl-methanone Ligands for Nicotinic Acetylcholine Receptors, Useful for the Treatment of Disease | CHRNA7, CHRNA6, CHRNA5 | LMNA 1274/4885MTNR1A 336/4885MTNR1B 441/4885 |
| US-20090131384-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF DISORDERS ASSOCIATED WITH ER STRESS | NR1H3, NR1H2, SREBF1 | LMNA 583/4885MTNR1A 890/4885MTNR1B 1015/4885 |
| US-20200299306-A1 | COMPOUNDS WITH A BENZO[A]CARBAZOLE STRUCTURE AND USE THEREOF | MKI67, CCNI, CASP3 | LMNA 640/4885MTNR1A 1352/4885MTNR1B 1273/4885 |
| US-20060052410-A1 | 6H-[1]benzopyrano[4,3-b]quinolines and their use as estrogenic agents | CYP19A1, ESR1, ESR2 | LMNA 1708/4885MTNR1A 157/4885MTNR1B 98/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.